According to this report, the global insulin market is estimated to be valued at US$ 60 billion in the year 2025, growing at a CAGR of 8% in the period 2019 to 2025. Growth of the market is driven by factors such as prevalence of diabetes cases, ageing population and growing obese population.
Insulin is a peptide hormone produced by beta cells of the pancreas. It is mainly associated with regulation of metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood and protein synthesis. It is mainly administered through subcutaneous injection using various insulin delivery devices such as Vials & Syringes, Insulin Pens, Insulin Pumps and Insulin Jet Injectors.
Insulin market has witnessed many firsts in the year 2019. This includes advent of first glucagon-like peptide (GLP-1) Rybelsus oral tablets. Secondly, FDA has also approved world's first Artificial Pancreas developed by UVA.
This report provides a detailed analysis of the global insulin and insulin delivery devices market from qualitative and quantitative outlooks during the forecast period across various classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Base year: 2014
Forecast period: 2020-2025
Market sizing Revenue in US$ Billions & CAGR for the period 2014 to 2025
Country coverage: The US, The UK, Germany, France, Italy, China, India & Japan
Vendor scope Novo Nordisk, Sanofi Aventis, Eli Lilly & Company, Merck & Co., Beckton Dickinson
Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the market has been segmented on the basis of delivery device classes and region.
7. Regional Analysis 7.1 Europe 7.2 North America and Caribbean 7.3 Asia-Pacific
8. Pricing Analysis
9. Global Insulin Market Dynamics 9.1 Industry Trends & Developments 9.1.1 Approval of First Oral GLP-1 9.1.2 Advent of Reusable Smart Insulin Pens 9.1.3 Approval of First Artificial Pancreas System 9.1.4 Next-Generation Insulin Management System Platform 9.2 Growth Drivers 9.2.1 Prevalance of Diabetes 9.2.2 Rise in Geriatric Population 9.2.3 Growing Obese Population 9.2.4 Propagation of Diabetes Management Awareness 9.2.5 Government Impetus 9.3 Challenges 9.3.1 High Cost of Insulin Pumps 9.3.2 Insufficient Reimbursement 9.3.3 Stringent Regulatory Compliance